Why the study?
Does GSK-3β heterozygous knockout prevent heart failure progression and extend lifespan in a mouse model of familial dilated cardiomyopathy?
Does GSK-3β heterozygous knockout prevent heart failure progression and extend lifespan in a mouse model of familial dilated cardiomyopathy?
Heterozygous knockout of GSK-3β is cardioprotective and extends lifespan in a mouse model of familial dilated cardiomyopathy caused by a ΔK210 cTnT mutation.
GSK-3β reduction may attenuate genetic DCM progression in mice; leaves open translation to human therapy.
Glycogen synthase kinase-3β (GSK-3β) plays a central role in both cardiac physiology and pathology. Herein we want to clarify the role of GSK-3β in familial dilated cardiomyopathy. We generated a mouse model carrying a heterozygous knockout mutation of GSK-3β (GSK-3β(+/-) KO), together with a ΔK210 knockin mutation in cardiac troponin T (ΔK210 cTnT KI), which was proved to be one of the genetic causes of familial dilated cardiomyopathy (DCM). GSK-3β(+/-) KO prevented the slow and rapid deterioration in left ventricular systolic function accompanying heart failure (HF) in DCM mice with heterozygous and homozygous ΔK210 cTnT KI mutations, respectively. GSK-3β(+/-) KO also prevented cardiac enlargement, myocardial fibrosis, and cardiomyocyte apoptosis and markedly reduced the expression of cardiac β-myosin heavy chain isoform, indicative of HF, in DCM mice with homozygous ΔK210 cTnT KI mutation. GSK-3β(+/-) KO also extended the life span of these DCM mice. This study suggests that the inhibition of GSK-3β is cardioprotective in familial DCM associated with ΔK210 cTnT mutation.
No takes yet. Share an insight, caveat, or question.
Mohamed et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: